Surveillance and screening for Barrett esophagus and adenocarcinoma

Journal of Clinical Gastroenterology

Volumn 39, Issue 4 SUPPL., 2005, Pages

  Mashimo, Hiroshi ^a   Wagh, Mihir S ^a   Goyal, Raj K ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

Adenocarcinoma; Barrett's esophagus; Dysplasia; Surveillance

Indexed keywords

BARRETT ESOPHAGUS; CANCER DIAGNOSIS; CANCER SCREENING; DISEASE COURSE; DISEASE MARKER; DYSPLASIA; EARLY CANCER; ENDOSCOPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; HUMAN; PRIORITY JOURNAL; RELIABILITY; REVIEW;

EID: 15444370304     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000155859.26557.45     Document Type: Review

References (52)

1. Spechler SJ, Goyal RK. Barrett's Esophagus: Pathophysiology, Diagnosis and Management. New York: Elsevier, 1985.
2. Sharma P, Sampliner RE. Barrett's Esophagus and Esophageal Adenocarcinoma. Malden, MA: Blackwell, 2001.
3. Spechler SJ. Barrett's esophagus. N Engl J Med. 2002;346:836-842.
4. Naef AP, Savary M, Ozzello L. Columnar-lined esophagus: an acquired condition with malignant predisposition, report on 140 cases of Barrett's esophagus with 12 adenocarcinomas. J Thorac Cardiovasc Surg. 1975;70: 826-835.
5. Trier JS. Morphology of the epithelium of the distal esophagus in patients with mid esophageal strictures. Gastroenterology. 1970;58:444-461.
6. Sampliner RE. Practice guidelines on the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol. 1998;93:1028-1032.
7. Sabik JF, Rice TW, Goldblum JR, et al. Superficial esophageal carcinoma. Ann Thorac Surg. 1995;60:896-902.
8. Devessa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998; 83:2049-2053.
9. Lagergren J, Bergstrom R, Lindren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825-831.
10. Sampliner RE, and the Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol. 2002; 97:1888-1895.
11. Levine DS, Reid BJ. Endoscopic technique for acquiring larger mucosal samples. Gastrointest Endosc. 1991;37:332-337.
12. Buttar NS, Wang KK, Sebo TJ, et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology. 2001;120:1630-1639.
13. Pacifico RJ, Wang KK, Wongkeesong LM, et al. Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus. Clin Gastroenterol Hepatol. 2003;1:252-257.
14. Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol. 1994;25:982-993.
15. Schnell TG, Sontag SJ, Chejfec G, et al. Long-term non-surgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology. 2001;120:1607-1619.
16. Levine DS. Management of dysplasia in the columnar-lined esophagus. Gastroenterol Clin North Am. 1997;26:613-634.
17. Stein HJ. Esophageal cancer: screening and surveillance. Results of a consensus conference held at the VIth World Congress of the International Society for Diseases of the Esophagus. Dis Esophagus. 1996; 9(suppl):3-19.
18. Headrick JR, Nichols FC 3rd, Miller DL, et al. High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy. Ann Thorac Surg. 2002;73:1697-1702.
19. Birkmyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346:1128-1137.
20. Gillen P, Keeling P, Byrne PJ, et al. Implication of duodenogastric reflux in the pathogenesis of Barrett's oesophagus. Br J Surg. 1988;75: 540-543.
21. Paull A, Trier JS, Dalton MD, et al. The histologic spectrum of Barrett's esophagus. N Engl J Med. 1976;295:476-480.
22. Spechler SJ, Zeroogian JM, Antonioli DA, et al. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet. 1994;344: 1533-1536.
23. Pera M. Trends in incidence and prevalence of specialized intestinal metaplasia, Barrett's esophagus, and adenocarcinoma of the gastroesophageal junction. World J Surg. 2003;27:999-1008.
24. Falk GW. Barrett's esophagus. Gastroenterology. 2002;122:1569-1591.
25. Sharma P, Morales TG, Bhattacharyya A, et al. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up. Am J Gastroenterol. 1997;92:2012-2016.
26. Alikhan M, Rex D, Khan A, et al. Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest Endosc. 1999;50:23-26.
27. Reid BJ, Haggitt RC, Rubin CE, et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol. 1988;19:166-178.
28. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001;32:368-378.
29. Sharma P, Falk G, Weston AP, et al. Natural history of LGD, an infrequent finding which usually regresses: preliminary results from the Barrett's esophagus study. Gastroenterology. 2002;122:156.
30. Fang M, Lew E, Klein M, et al. DNA abnormalities as marker of risk for progression of Barrett's esophagus to adenocarcinoma: image cytometric DNA analysis in formalin-fixed tissues. Am J Gastroenterol. 2004;99: 1887-1894.
31. Reid BJ, Levine DS, Longton G, et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol. 2000;95:1669-1676.
32. Corley DA, Levin TR, Habel LA, et al. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology. 2002;122:633-640.
33. Streitz JM, Jr., Andrews CW, Ellis FH, Jr. Endoscopic surveillance of Barrett's esophagus: Does it help? J Thorac Cardiovasc Surg. 1993;105:383-387.
34. Peters JH, Clark GW, Ireland AP, et al. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg. 1994;108:813-821.
35. VanSandick JW, Lanschot JJ, Kuiken BW, et al. Impact of endoscopic biopsy surveillance of Barrett's esophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut. 1998;43:216-222.
36. Sharma P, Topalovski M, Mayo MS, et al. Methylene blue chromoendoscopy for detection of short-segment Barrett's esophagus. Gastrointest Endosc. 2001;54:289-293.
37. Endlicher E, Knuechel R, Hauser T, et al. Endoscopic fluorescence detection of low and high grade dysplasia in Barrett's oesophagus using systemic or local 5-aminolaevulinic acid sensitisation. Gut. 2001;48:314-319.
38. Wallace MB, Perelman LT, Backman V, et al. Endoscopic detection of dysplasia in patients with Barrett's esophagus using light-scattering spectroscopy. Gastroenterology. 2000;119:677-682.
39. Li XD, Boppart SA, Van Dam J, et al. Optical coherence tomography: advanced technology for the endoscopic imaging of Barrett's esophagus. Endoscopy. 2000;32:921-930.
40. Spechler SJ. Disputing dysplasia. Gastroenterology. 2001;120:1864-1868.
41. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100: 57-70.
42. Rabinovitch PS, Longton G, Blount PL, et al. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol. 2001;96:3071-3083.
43. Lieberman DA, Oehlke M, Helfand M. Risk factors for Barrett's esophagus in community based practice. Am J Gastroenterol. 1997;92:1293-1297.
44. Eisen GM, Sandler RS, Murray S, et al. The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus. Am J Gastroenterol. 1997;92:27-31.
45. Lagergren J, Bergstrom R, Lindren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825-831.
46. Chak A, Lee T, Kinnard MF, et al. Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. Gut. 2002;51:323-328.
47. Shaheen NJ, Crosby MA, Bozymski EM, et al. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology. 2000;119:333-338.
48. Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology. 2003;125:1670-1677.
49. Anderson LA, Murray LJ, Murphy SJ, et al. Mortality in Barrett's oesophagus: results from a population based study. Gut. 2003;52:1081-1084.
50. Van der Burgh A, Dees J, Hop WCJ, et al. Oesophageal cancer is an uncommon cause of death in patients with Barrett's esophagus. Gut. 1996; 39:5-8.
51. Dulai GS, Guha S, Kahn KL, et al. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology. 2002;122:26-33.
52. Inadomi JM, Sampliner R, Lagergren J, et al. Screening and surveillance for Barrett's esophagus in high-risk populations: a cost-utility analysis. Ann Intern Med. 2003;138:176-186.